Abstract
A higher BMI is prospectively associated with an increased risk of developing sarcoidosis in women http://ow.ly/OQ6k30f7XaQ
To the Editor:
Sarcoidosis is a systemic inflammatory disorder, characterised by the formation of immune granulomas that can occur in various organs, but typically affects the lungs [1]. Although sarcoidosis resolves spontaneously in many cases, about one-third of patients experience chronic disease associated with significant morbidity [2].
Although the exact causes of sarcoidosis remain unknown, it is thought to result from an exaggerated immune response to yet unidentified antigens in individuals with genetic susceptibility [1]. Geographical variations in sarcoidosis occurrence support the existence of environmental risk factors [3–5]. Research into the potential causes of sarcoidosis has focused on occupational and environmental exposures [6, 7], but lifestyle-related risk factors have not been as extensively examined.
The proinflammatory milieu of obesity appears to favour the development of other inflammation-related diseases, such as asthma [8]. Recently, a study of African-American women found that obesity was prospectively associated with a higher risk of incident sarcoidosis [9]. Black Americans are known to have an increased risk of sarcoidosis compared to white Americans, and risk factors may differ across these two populations. Although an association between obesity and sarcoidosis has also been suggested in two studies of predominantly white populations [10, 11], data were either cross-sectional or included limited information regarding weight change over time and potential confounders. In the current study, we aimed to investigate the prospective association of body mass index (BMI) and weight change with a 24-year incidence of sarcoidosis in a large cohort of female nurses in the U.S.
The Nurses' Health Study II (NHSII) began in 1989, when 116 430 female registered nurses from 14 U.S. states, aged 25–44 years, completed a mailed questionnaire on their medical history and lifestyle characteristics [3]. Follow-up questionnaires have been sent every 2 years since. The active follow-up rate (number of person-years in the cohort, when participants are censored after their last questionnaire response) from 1989 to 2013 was 86% of the potential person-years. The study was approved by the local Institutional Review Board.
In all questionnaires, participants were asked to report any physician-diagnosed condition(s) that they had ever experienced (baseline) or with which they were diagnosed since the last questionnaire cycle (follow-up). Although no specific question on sarcoidosis was included, participants were asked to report “other major illness” in a final free-text field. We used this information to identify cases of physician-diagnosed sarcoidosis from 1989–2013. Although cases have not been validated by medical records, the validity of these nurses' health outcomes reports is generally >80% for other conditions [12]. Furthermore, a 96% agreement between self-report of sarcoidosis diagnosis and physician's report has been reported in the Black Women's Health Study [9].
Current height and weight, and weight at age 18 years were reported on the baseline questionnaire. Current weight was updated in all subsequent biennial questionnaires. Race (white, black, others), smoking status (never, ex- or current smoker) and pack-years (continuous), U.S. region (West, Midwest, South, Northeast), household income (>$44 500 versus ≤$44 500), husband's education (high school or less, college graduate, graduate degree), physical activity (<3, 3–8.9, 9–17.9, 18–26.9, 27–41.9, ≥42 metabolic equivalents (METs) per week) and alcohol consumption (0, 0.01–5, 5.01–10, >10 g/day) were examined as potential confounders [9, 10]. Associations of current BMI (i.e., BMI at the questionnaire cycle before diagnosis), BMI at age 18 years, and weight change since age 18 years, with sarcoidosis incidence were evaluated using Cox proportional hazard models. All Cox models were stratified by age in months and calendar year. A two-sided p<0.05 was considered statistically significant. All analyses were run using the SAS V.9 software (SAS Institute, Cary, NC, USA).
The study population consisted of 116 312 women, without a history of sarcoidosis at baseline. At baseline, participants were on average 34 years old; 96% were white, 14% were current smokers and 21% were ex-smokers. The BMI at baseline was <20 kg·m−2 in 15% of the participants; 20 to 24.9 kg·m−2 in 54%; 25 to 29.9 kg·m−2 (overweight) in 19%; and ≥30 kg·m−2 (obesity) in 12%.
During 2 457 150 person-years of follow-up, from 1989 to 2013, 270 incident cases were reported. Higher current BMI was associated with increased risk of developing sarcoidosis during follow-up (p-trend<0.001, table 1). Similar results were observed in multivariable-adjusted models (p-trend<0.001), with significant associations in both overweight (hazard ratio (HR) 1.53, 95% CI 1.12–2.10) and obese (HR 1.74, 95% CI 1.26–2.40) women. Results were confirmed in a sensitivity analysis, in which sarcoidosis cases were restricted to participants who specifically indicated that the diagnosis occurred within 2 years before the questionnaire cycle during which they first reported sarcoidosis (n=174). Stronger associations were found for the risk of sarcoidosis incidence in overweight (HR 1.75, 95% CI 1.18–2.59) and obese (1.94, 1.30–2.91) women.
Prospective association between body mass index (BMI) and sarcoidosis incidence in women in the Nurses’ Health Study II [3]
To rule out potential reverse causation (i.e., symptoms of sarcoidosis before diagnosis affecting weight), we examined the association between BMI at age 18 years and sarcoidosis incidence during follow-up. Although associations were attenuated compared to current BMI, a significant positive trend was observed between BMI at age 18 years and sarcoidosis incidence (p-trend=0.009, table 1). Higher weight gain since age 18 years was also associated with increased risk of sarcoidosis incidence (p-trend=0.02).
In this large cohort of predominantly white U.S. women, increased risks of sarcoidosis were observed in both overweight and obese participants. Consistent findings have been reported in a Danish register-based study examining the association between pre-pregnancy BMI in women and the development of several disorders, including sarcoidosis [10]. Similar results have also been reported in a population of black women in the U.S. [9], but only for those with morbid obesity (BMI≥35 kg·m−2).
Chronic systemic inflammation associated with adiposity is suspected to have a role in the development of many disorders, including respiratory [8] and autoimmune diseases [10]. Adipokines produced in the obese adipose tissue have broad immunomodulatory effects. In particular, they could induce a proinflammatory process in the lungs [8, 9], which is involved in most sarcoidosis cases. Furthermore, some investigators have suggested that the exaggerated inflammatory response to a causal antigen, leading to the formation of granulomas in sarcoidosis might occur, or be enhanced, in an inflammatory environment [13]. Our results are consistent with the hypothesis that adiposity-related inflammation could contribute to the development of sarcoidosis.
In summary, this analysis of a large cohort of U.S. women followed-up over 24 years showed that higher BMI and weight gain was prospectively associated with a higher risk of incident sarcoidosis. Given the elevated prevalence of overweight and obesity in the U.S. and other developed countries, and limited understanding of sarcoidosis aetiology, the potential impact of adiposity-related inflammation merits further investigation.
Acknowledgements
The Nurses’ Health Study II is coordinated at the Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA. We would like to thank the participants and staff of the Nurses’ Health Study II for their valuable contributions.
Footnotes
Support statement: Funding was provided by the National Institutes of Health (UM1 CA176726). Funding information for this article has been deposited with the Crossref Funding Registry.
Conflict of interest: None declared.
- Received July 12, 2017.
- Accepted July 17, 2017.
- Copyright ©ERS 2017